By writing a custom computer algorithm that mapped every possible version of a rare class of geometric shapes, 17-year-old ...
Vertex Pharmaceuticals (NASDAQ:VRTX) stock drew attention as gene therapy sales climbed and an expanded approval broadened ...
For years, enterprise buyers have relied on vendors' internal metrics — low attrition rate, Glassdoor ratings, employer-brand ...
Vertex Pharmaceuticals is executing a pivotal transition year, evolving from a CF-dominated biotech to a multi-franchise ...
Good morning, and welcome to the Vertex First (sic) [ Second ] Quarter 2026 Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded. If you have any objections, please ...
Drawing on more than 2,100 enterprise leaders across two independent research firms, the findings reveal two compounding forces - Defensibility Drift and CompOps Drag - that widen a Compliance Confide ...
(NASDAQ: VERX) (“Vertex” or the “Company”) , the Decision-to-Defense™ global indirect tax and compliance company, today released new research pointing to a structural shift in how global enterprises ...
First, let's take a look at Vertex's portfolio and general situation prior to the Crinetics move. As mentioned, the biotech is the global CF leader, specializing in CFTR modulators. These therapies ...
Vertex Pharmaceuticals has struck a $10 billion deal—its largest ever—to acquire Crinetics Pharmaceuticals. And while the transaction brings Vertex a newly approved potential blockbuster in Palsonify, ...
Vertex Pharmaceuticals VRTX1.28%increase; up pointing triangle has agreed to purchase Crinetics Pharmaceuticals CRNX 0.17%increase; up pointing triangle for $10 billion, adding a biopharmaceutical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results